BAL, has been smashed down around 60% from recent high, punished for the delay of SAMR approval.
However, BAL expects 2018 annual revenue to be around $312m - $324m with EBITDA of 21-23%.
BAL's infant formula revenue for 2018 year would be around A$300m,
A2M's infant formula revenue for 2018 year would be around A$720m, EBITDA of 30%, with CFDA/SAMR approval.
A2M's market cap is Seven times of BAL's.
BAL does have organic certificate to apply for CNCA, also the source of organic powder is an issue.
- Forums
- ASX - By Stock
- BAL
- Fundamentals
Fundamentals
-
- There are more pages in this discussion • 243 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BAL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online